Lindy Bancke

Safety of fecal microbiota, live-jslm (REBYOTA^™) in individuals with recurrent <i>Clostridioides difficile</i> infection: data from five prospective clinical trials

Christine Lee, Thomas Louie, Lindy Bancke et al. · Therapeutic Advances in Gastroenterology · 2023 · 68 citations · Full text

Pharmacokinetics, pharmacodynamics, and safety of <scp>USL</scp>261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers

Lindy Bancke, Heather A. Dworak, Keith A. Rodvold et al. · Epilepsia · 2015 · 31 citations · Full text

PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent <i>Clostridioides difficile</i> Infection

Paul Feuerstadt, Teena Chopra, W Knapple et al. · Clinical Infectious Diseases · 2024 · 24 citations · Full text

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent <i>Clostridioides difficile</i> Infection: Results From the PUNCH CD3 Clinical Trial

Kevin W. Garey, Erik R. Dubberke, Amy Guo et al. · Open Forum Infectious Diseases · 2023 · 21 citations · Full text

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTATM) Administered Under Enforcement Discretion to Patients With <i>Clostridioides difficile</i> Infection

Paul Feuerstadt, Adam Harvey, David S Yoho et al. · Open Forum Infectious Diseases · 2023 · 17 citations · Full text